Actelion Ltd. entered potentially it's biggest ever deal, a strategic collaboration in the area of orexin antagonists with GlaxoSmithKline plc that could be worth up to CHF3.3 billion (US$3.2 billion) ...
An investigational oral selective orexin receptor 2 agonist (oveporexton, Takeda) demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults ...
Cognitive symptoms associated with narcolepsy type 1 are common, particularly in sustaining attention and processing information. Oveporexton improved attention, memory, and executive function over 8 ...
– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 – Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight ...
The investigational orexin receptor 2 (OX2R) agonist oveporexton improved cognitive symptoms of narcolepsy type 1 (NT1) in secondary analysis of a phase II trial. The oral agent improved attention, ...
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results